Use of nicotinamide to treat hyperphosphatemia in dialysis patients

Drugs in R and D

Volumn 13, Issue 3, 2013, Pages 165-173

  Lenglet, Aurélie ^a,b   Liabeuf, Sophie ^a,b   Guffroy, Pauline ^a,b   Fournier, Albert ^b   Brazier, Michel ^a,b   Massy, Ziad A ^a,c  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM ACETATE; CALCIUM CARBONATE; LANTHANUM CARBONATE; MAGNESIUM ACETATE; MAGNESIUM HYDROXIDE; NICOTINAMIDE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE;

BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCIUM BLOOD LEVEL; CLINICAL STUDY; DIALYSIS; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEALTH; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY PROXIMAL TUBULE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SYSTEMIC CIRCULATION;

HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; NIACINAMIDE; PHOSPHATES; RENAL DIALYSIS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS; TISSUE DISTRIBUTION;

EID: 84885600404     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0024-6     Document Type: Review

References (57)

1. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520-8.
2. Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, Slama M, et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res. 2012;96:130-9.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-17.
4. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-8.
5. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008;19:1092-105.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130.
7. Lumlertgul D, Burke TJ, Gillum DM, Alfrey AC, Harris DC, Hammond WS, et al. Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int. 1986;29:658-66.
8. Haut LL, Alfrey AC, Guggenheim S, Buddington B, Schrier N. Renal toxicity of phosphate in rats. Kidney Int. 1980;17:722-31.
9. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis. 1997;29:641-9.
10. Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986;30:753-9.
11. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362:1312-24.
12. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol. 2005;16(Suppl 2):S107-14.
13. Hutchison AJ, Smith CP, Brenchley PEC. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7:578-89.
14. Bellasi A, Kooienga L, Block GA. Phosphate binders: new products and challenges. Hemodial Int. 2006;10:225-34.
15. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407-15.
16. Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487-93.
17. Chase P, Dupre J, Mahon J, Ehrlich R, Gale E, Kolb H, et al. Nicotinamide and prevention of diabetes. Lancet. 1992;339:1051-2.
18. Gale EAM, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363:925-31.
19. Denekamp J, Fowler JF. ARCON - current status: summary of a workshop on preclinical and clinical studies. Acta Oncol. 1997;36:517-25.
20. Smythies JR. Letter: nicotinamide treatment of schizophrenia. Lancet. 1973;2:1450-1.
21. Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care. 1996;19:1357-63.
22. Karpe F, Frayn KN. The nicotinic acid receptor - a new mechanism for an old drug. Lancet. 2004;363:1892-4.
23. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18:415-20.
24. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101:S20-6.
25. Sampathkumar K. Niacin and analogs for phosphate control in dialysis-perspective from a developing country. Int Urol Nephrol. 2009;41:913-8.
26. Kirkland JB. Niacin status impacts chromatin structure. J Nutr. 2009;139:2397-401.
27. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol. 2008;153(Suppl 1):S68-75.
28. Berndt TJ, Pfeifer JD, Knox FG, Kempson SA, Dousa TP. Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol. 1982;242:F447-52.
29. Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest. 1981;67:1347-60.
30. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant. 2005;20:1378-84.
31. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant. 1999;14:1195-201.
32. Sabbagh Y, O'Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol. 2009;20:2348-58.
33. Schiavi SC, Tang W, Bracken C, O'Brien SP, Song W, Boulanger J, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012;23:1691-700.
34. Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes. 1995;44:152-5.
35. Stratford MR, Dennis MF, Hoskin P, Phillips H, Hodgkiss RJ, Rojas A. Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring. Br J Cancer. 1996;74:16-21.
36. Dragovic J, Kim SH, Brown SL, Kim JH. Nicotinamide pharmacokinetics in patients. Radiother Oncol. 1995;36:225-8.
37. Rutkowski P, Slominska EM, Wołyniec W, Smoleński RT, Szolkiewicz M, Swierczyński J, et al. Nicotinamide metabolites accumulate in the tissues of uremic rats. J Ren Nutr. 2008;18:56-9.
38. Gillmor HA, Bolton CH, Hopton M, Moore WP, Perrett D, Bingley PJ, et al. Measurement of nicotinamide and N-methyl-2-pyridone-5-carboxamide in plasma by high performance liquid chromatography. Biomed Chromatogr. 1999;13:360-2.
39. Rutkowski B, Slominska E, Szolkiewicz M, Smolenski RT, Striley C, Rutkowski P, et al. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl. 2003;(84):S19-21.
40. Slominska EM, Kowalik K, Smolenski RT, Szolkiewicz M, Rutkowski P, Rutkowski B, et al. Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure. Pediatr Nephrol. 2006;21:800-6.
41. Rutkowski B, Rutkowski P, Słomińska E, Smolenski RT, Swierczyński J. Cellular toxicity of nicotinamide metabolites. J Ren Nutr. 2012;22:95-7.
42. Knip M, Douek IF, Moore WPT, Gillmor HA, McLean AEM, Bingley PJ, et al. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43:1337-45.
43. Beyer KH, Russo HF. Renal tubular elimination of N1-methylnicotinamide. Am J Physiol. 1950;160:311-20.
44. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RNP. Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol. 2006;38:171-4.
45. Müller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol. 2007;2:1249-54.
46. Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia. Nefrologia. 2008;28:61-6.
47. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol. 2010;5:582-9.
48. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65:1099-104.
49. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1131-8.
50. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int. 2009;29:562-7.
51. Shahbazian H, Zafar Mohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, Hayati F, et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. Nefrologia. 2011;31:58-65.
52. Vasantha J, Soundararajan P, Vanitharani N, Kannan G, Thennarasu P, Neenu G, et al. Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. Indian J Nephrol. 2011;21:245-9.
53. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-87.
54. Delanaye P, Weekers L, Krzesinski JM. Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int. 2006;69:1914.
55. 3 (nicotinamide). N Engl J Med. 1973;289:1180-2.
56. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int. 2005;68:2911-2.
57. Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008;24:601-8.